Xience (everolimus-eluting stent) / Abbott - LARVOL DELTA

NOVA: Noninferiority Trial Of Sirolimus With Ascorbic Acid Versus Everolimus in All-comers (clinicaltrials.gov) - P=N/A | N=2034 | Not yet recruiting | Sponsor: Jung-min Ahn | Initiation date: Jun 2026 ➔ Oct 2026

Head-to-Head • Trial initiation date • Cardiovascular • Coronary Artery Disease

Angiographic and Clinical Outcomes After Everolimus-Eluting Stent Implantation for Cardiac Allograft Vasculopathy: A Systematic Review and Single-Arm Meta-Analysis (AHA 2026) - "Abstract is embargoed at this time."

Clinical data • Retrospective data • Review • Cardiovascular

Coronary porcine studies of mechanical, morphometric, and physiological performance based on OCT /angiography of CD31‑endothelial‑mimetic coating stent, drug-eluting stent and bare metal stent (ESC 2026) - "Purpose: Mechanical, morphometric and physiological performances of the SP1072-coated cobalt-chromium stent CD31 stent was compared with a contemporary everolimus-eluting stent and a bare metal stent (BMS, L605 cobalt chromium) in a healthy porcine coronary model, using both angiography and optical coherence tomography (OCT) post procedure and at 28 days... In this study of healthy porcine coronary arteries, CD31-coated stents ,DES and BMS were exposed to similar baro-trauma and exhibited comparable acute recoil. At 28 days in this small exploratory pilot study the 3 stents showed comparable minimal luminal area with OCT,did not exhibit binary restenosis (DS>50%) or flow limitation below the threshold of QFR<0.80.These preliminary results mandated further experimentation in restenotic and atherosclerotic porcine model."

Preclinical • Atherosclerosis • Cardiovascular • CD31 • PECAM1

Assessment and contributing factors of adequate endothelization after drug-eluting stent implantation (ESC 2026) - "Four DES types were evaluated: durable polymer everolimus-eluting stents (DP-EES), sirolimus-eluting stents (SES), polymer-free biolimus-coated stents (PF-BCS), and dual-therapy sirolimus-eluting stents (DTS). Assessment of adequate endothelialization after DES implantation using OCT is more reliable at 12 months than at 1 month post-procedure. The optimal %ASC thresholds at 12 months are 67% for thrombus prevention and 90% for plaque stabilization. Use of prasugrel and ingenious DES may favorably influence chronic endothelialization after DES implantation."

Cardiovascular • Hypertension • Thrombosis

PRISON-IV: Hybrid Sirolimus-eluting Versus Everolimus-eluting Stents for Total Coronary Occlusions (clinicaltrials.gov) - P=N/A | N=330 | Completed | Sponsor: R&D Cardiologie | Unknown status ➔ Completed | Phase classification: P3 ➔ PN/A

Phase classification • Trial completion • Cardiovascular • Coronary Artery Disease

Bioresorbable-polymer sirolimus-eluting stents versus durable-polymer everolimus-eluting stents in percutaneous coronary intervention: A systematic review and meta-analysis of randomized controlled trials with GRADE assessment. (PubMed, JRSM Cardiovasc Dis) - "Higher binary restenosis increased target lesion revascularisation with fully BRS indicate that these platforms are not interchangeable with contemporary metallic stents. Further large, long-term trials are required."

Journal • Retrospective data • Review • Cardiovascular • Myocardial Infarction

Long-Term Outcomes With Biodegradable Polymer Biolimus-Eluting Stents Versus Durable Polymer Everolimus-Eluting Stents for Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Controlled Trials. (PubMed, Cardiol Rev) - "In patients undergoing PCI, BP-BES demonstrates long-term clinical outcomes comparable to DP-EES. These findings support the long-term safety and effectiveness of BP-BES."

Journal • Retrospective data • Cardiovascular • Myocardial Infarction

Baseline Anemia and Short Dual Antiplatelet Therapy in High Bleeding Risk Patients Undergoing Percutaneous Coronary Intervention. (PubMed, Eur J Prev Cardiol) - "Among HBR patients undergoing PCI, abbreviated DAPT was associated with comparable ischemic outcomes regardless of anemia status. In patients with baseline anemia, 1-month DAPT was associated with lower major bleeding without an apparent ischemic trade-off."

Journal • Anemia • Cardiovascular • Hematological Disorders • Myocardial Infarction

Abbreviated DAPT Regimens Across the Entire Spectrum of Bleeding Risk According to the PRECISE-HBR Score. (PubMed, JACC Cardiovasc Interv) - "The PRECISE-HBR score identified patients at increased risk for both bleeding and ischemic events who seemed to derive greater benefit from 1-month DAPT after stent implantation."

Journal • Cardiovascular • Myocardial Infarction

BIOMAG-II: Safety and Clinical Performance of the Freesolve Resorbable Magnesium Scaffold System (clinicaltrials.gov) - P=N/A | N=1861 | Active, not recruiting | Sponsor: Biotronik AG | Recruiting ➔ Active, not recruiting

Enrollment closed • Acute Coronary Syndrome • Atherosclerosis • Cardiovascular • Coronary Artery Disease • Heart Failure • Myocardial Ischemia

Ultra-Thin Sirolimus-Eluting Versus Everolimus-Eluting Stents in Diabetic Multivessel Coronary Artery Disease Patients: The TUXEDO-2 Trial. (PubMed, J Am Coll Cardiol) - "In patients with diabetes and multivessel disease undergoing percutaneous coronary intervention, ultra-thin biodegradable polymer SES was noninferior to durable polymer EES at 1 year follow-up. (Trial Registration Number CTRI/2019/11/022088)."

Journal • Cardiovascular • Coronary Artery Disease • Diabetes • Hematological Disorders • Metabolic Disorders • Myocardial Infarction • Thrombosis

Everolimus-Eluting Stent (Espalier) in Coronary Artery Revascularization: A Retrospective, Investigator-Initiated, Multicenter Study. (PubMed, Cardiol Res) - "Device and procedural success were achieved in all cases (100%), with no failures recorded. The Espalier EES demonstrated high procedural success and low adverse event rates at 12 months, with slightly higher risks observed in elderly and high-risk patients."

Clinical • Journal • Retrospective data • Cardiovascular • Hematological Disorders • Myocardial Infarction • Thrombosis

Comparative effectiveness of Orsiro, Xience, Synergy, and Resolute stent in patients with acute myocardial infarction undergoing percutaneous coronary intervention: a nationwide registry study. (PubMed, Coron Artery Dis) - "In this large-scale, real-world AMI cohort, the ultrathin-strut, biodegradable-polymer Orsiro stent was associated with a lower risk of repeat revascularization compared with the Synergy and Resolute stents. Xience demonstrated comparable outcomes to Orsiro. Stent selection remains a crucial determinant of vessel-level outcomes in patients with AMI."

HEOR • Journal • Cardiovascular • Myocardial Infarction

BIOMAG-III: Safety and Clinical Performance of the Freesolve Resorbable Magnesium Scaffold (RMS) System in Subjects With Coronary Artery Lesions (clinicaltrials.gov) - P=N/A | N=1859 | Recruiting | Sponsor: Teleflex | Not yet recruiting ➔ Recruiting

Enrollment open • Acute Coronary Syndrome • Atherosclerosis • Cardiovascular • Coronary Artery Disease • Heart Failure • Myocardial Ischemia • Pain

SPIES: Systematic Post-Implementation Evaluation of Stents (clinicaltrials.gov) - P=N/A | N=1067 | Completed | Sponsor: Vastra Gotaland Region | Recruiting ➔ Completed | N=6000 ➔ 1067

Enrollment change • Trial completion • Cardiovascular • Myocardial Ischemia

A Trial of Firesorb in Patients With Coronary Artery Disease: FUTURE-II (clinicaltrials.gov) - P=N/A | N=430 | Completed | Sponsor: Shanghai MicroPort Medical (Group) Co., Ltd. | Active, not recruiting ➔ Completed

First-in-human • Trial completion • Cardiovascular • Coronary Artery Disease

OPEN-ISR: Optimal Treatment for Coronary Drug Eluting Stent In-stent Restenosis (clinicaltrials.gov) - P=N/A | N=108 | Completed | Sponsor: Semmelweis University Heart and Vascular Center | Recruiting ➔ Completed

Trial completion

Fetal Intervention Using an Everolimus-Eluting Stent in HLHS With Intact Atrial Septum. (PubMed, JACC Case Rep) - "In utero use of an everolimus-eluting stent appears safe and may reduce the risk of in-stent obstruction in fetuses with HLHS and IAS."

Journal • Cardiovascular • Hypertension

ANGIODAPT: Ischemic and Bleeding Outcomes After Angiolite Stent Implantation and an Abbreviated Dual Antiplatelet Therapy (clinicaltrials.gov) - P3 | N=2312 | Active, not recruiting | Sponsor: iVascular S.L.U. | Trial completion date: Aug 2030 ➔ Jan 2030 | Trial primary completion date: Aug 2026 ➔ Jan 2027 | Recruiting ➔ Active, not recruiting

Enrollment closed • Trial completion date • Trial primary completion date • Cardiovascular • Coronary Artery Disease

NOVA: Noninferiority Trial Of Sirolimus With Ascorbic Acid Versus Everolimus in All-comers (clinicaltrials.gov) - P=N/A | N=2034 | Not yet recruiting | Sponsor: Jung-min Ahn

Head-to-Head • New trial • Cardiovascular • Coronary Artery Disease

Re-evaluating Comparative Outcomes of Biodegradable and Durable Polymer Everolimus-Eluting Stents. (PubMed, Indian Heart J) - No abstract available

Journal

Ischaemic cardiomyopathy with a significant improvement in left ventricular wall motion following revascularization for a honeycomb-like structure of the left anterior descending artery: a case report. (PubMed, Eur Heart J Case Rep) - "Two everolimus-eluting stents were implanted in the LAD...As reported in previous studies focusing on honeycomb-like structure, this case also exhibited angiographic underestimation of stenosis and low FFR value reflecting the true haemodynamic severity. The pathogenesis of honeycomb-like structure-thrombus formation and spontaneous recanalization-may have triggered ischaemic preconditioning, resulting in the development of hibernating myocardium, which could explain the viable myocardium in this case."

Journal • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Heart Failure • Pulmonary Disease • Thrombosis

Patent Ductus Arteriosus Stenting in Infants with Duct-Dependent Pulmonary Circulation: An Indian Experience. (PubMed, Cardiology) - "The PDA stenting with the latest-generation drug-eluting coronary stents is found safe and clinically better palliative care strategy for patients with duct-dependent pulmonary circulation, resulting in improved procedural and follow-up outcomes."

Journal • Palliative care

Novel Bioresorbable Scaffold for the Treatment of Patients With Coronary Artery Disease: Could the Holy Grail Be Made of Iron? (PubMed, J Am Coll Cardiol) - No abstract available

Journal • Cardiovascular • Coronary Artery Disease

EPIC31-PRO-HEAL: Plan to Evaluate Early Endothelialization of a Polymer Free Sirolimus-eluting Coronary Stent System (VIVO ISARTM) Compared With Everolimus-eluting Durable Polymer Stent (XIENCE SkypointTM) in Patients Undergoing Percutaneous Coronary Intervention. (clinicaltrials.gov) - P=N/A | N=40 | Active, not recruiting | Sponsor: Fundación EPIC | Trial completion date: May 2026 ➔ Aug 2026 | Trial primary completion date: Apr 2026 ➔ Jul 2026

Trial completion date • Trial primary completion date • Cardiovascular • Coronary Artery Disease